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ADAMTS13 (a disintegrin-like and metalloprote--ase with thrombospondin type 1 
motifs 13) 
aHUS (atypical hemolytic uremic syndrome) 
CAPD (continuous ambulatory peritoneal dialysis) 
CR-TTP (chronic relapsing thrombotic thrombocytopenic purpura) 
DCM (disease-causing muation) 
DDAVP (1-desamino-8-D-arginine vasopressin) 
DIC (disseminated intravascular coagulation) 
FFP (fresh frozen plasma) 
HELLP (hemolysis, elevated liver-enzymes, low platelets)  
ITP (idiopathic thrombocytopenic purpura) 
MAHA (microangiopathic hemolytic anemia) 
SNP (single nucleotide polymorphism) 
SLE (systemic lupus erythematosus) 
TMA (thrombotic microangiopathies) 
TTP (thrombotic thrombocytopenic purpura) 
UL-VWFM (unusually large von Willebrand factor multimers) 
VWF-CP (von Willebrand factor-cleaving protease) 




















Upshaw–Schulman syndrome (USS) is an extremely rare hereditary deficiency 
of ADAMTS13 activity, termed congenital TTP. The clinical signs are usually mild 
during childhood, often the isolated thrombocytopenia. But their symptoms become 
evident when the patients have infections or get pregnant. We identified 43 
USS-patients in Japan, who ranged in age from early childhood to 79 years old. 
Analyzing the natural history of these USS patients based on ADAMTS13 gene 
mutations may characterize their clinical phenotypes. 
Severe neonatal jaundice that requires exchange blood transfusion, a hallmark of 
USS, was found in 18 of 43 patients (42%). During childhood, 25 of 43 patients were 
correctly diagnosed of USS without gender disparity. These 25 patients were 
categorized as having “the early-onset phenotype”. Between 15 and 45 years of age, 
15 were correctly diagnosed, and interestingly they were all female. The remaining 
three patients were all male and were diagnosed when they got older than 45 years of 
age, suggesting that they were “the late-onset phenotype”. Two of these 3 males 
developed sudden overt TTP when they were 55 and 63 years old. These two men 
had two different homozygous ADAMTS13 gene mutations, p.R193W/p.R193W and 
p.C1024R/p.C1024R, respectively. Both of which were not discovered in the US and 
Western countries. In vitro expression studies showed that these two proteins were 
consistently secreted into the culture medium but to a lesser extent and with reduced 
activity compared to the wild-type protein. Our results indicate that “the late-onset 
phenotype” of USS is formed with ethnic specificity. 
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Upshaw–Schulman syndrome (USS) is a hereditary deficiency in the activity of 
von Willebrand factor-cleaving protease (VWF-CP) [1], termed ADAMTS13 (a 
disintegrin-like and metalloprotease with thrombospondin type 1 motifs 13) [2-4]. In 
the absence of ADAMTS13, unusually large VWF multimers (UL-VWFMs) released 
from vascular endothelial cells are inappropriately cleaved, which induce platelet 
hyperagglutination under high shear stress [5]. Thus, USS is alternatively called 
congenital thrombotic thrombocytopenic purpura (TTP). On the other hand, 
approximately half of congenital atypical hemolytic uremic syndrome (aHUS) cases 
are caused by genetic mutations in complement regulatory factors, such as factor H, I, 
and B, and membrane cofactor protein, or thrombomodulin [6]. However, the 
majority of both TTP and HUS occur in the acquired form, and it has been said that 
TTP and HUS patients predominantly exhibit neurotropic and nephrotropic signs, 
respectively. Further, it is often difficult to discriminate between these two diseases 
in clinical practice [7-9] because both diseases are identified based on common 
pathological features termed thrombotic microangiopathies (TMAs), which are 
characterized by organ dysfunction due to platelet thrombi in the microvasculature, 
consumptive thrombocytopenia, and microangiopathic hemolytic anemia (MAHA) 
[10].  
The classic hallmarks of USS are severe neonatal jaundice with a negative 
Coombs test that requires an exchange blood transfusion and repeated childhood 
episodes of thrombocytopenia and MAHA that are reversed by infusions of fresh 
frozen plasma (FFP) [11]. However, recent studies indicated that the clinical signs of 
USS during childhood may be much milder than expected, and often an isolated 
thrombocytopenia occurs, causing physicians to sometimes overlook this important 
disease [12].  
Despite a lengthy history on clinical diagnoses of USS, only 10 years have passed 
since the disease-related enzyme, ADAMTS13, was discovered [3, 4, 13, 14]. 
Furthermore, USS is an extremely rare disease, and to date, it is estimated that there 
have been approximately 100 patients worldwide [15]. In this regard, Nara Medical 
University has functioned as a TMA referral center in Japan since 1998 and collected 
a large dataset of 919 patients with TMA between 1998−2008 [16]. In this registry, 
we identified 41 USS patients in 36 different families who ranged in age from early 
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childhood to 79 years old. Subsequently, until the end of March 2011, we have 
identified 2 new USS-patients belonged to different families in Japan. Analyzing the 
natural history of these 43 USS-patients will further our understanding of the clinical 
significance of ADAMTS13, which functions to regulate the size of platelet-thrombi 




In 1953, Dacie et al. [17] reviewed 12 patients with atypical congenital hemolytic 
anemia and identified a 6-year-old girl who had experienced repeated episodes of 
severe jaundice, thrombocytopenia, hemolytic anemia, and schistocytes since she 
was a newborn. Before first visiting Dacie, this patient had received a splenectomy 
but did not improve. She died of renal failure at 7 years of age. This patient was the 
third of four children, and both the first and second children were jaundiced at birth 
and died of hemorrhage at 2 years and 4 days old, respectively. The fourth child and 
the parents were asymptomatic. Thus, the authors concluded that these 3 patients 
must have a hitherto unrecognized hereditable blood disease.  
In the absence of any known concept of TTP, in 1960, Schulman et al. [18] 
reported an 8-year-old girl who had no coagulation abnormalities but repeated 
bleeding episodes due to chronic thrombocytopenia and MAHA. These symptoms 
dramatically improved with fresh plasma infusions, suggested that the patient had a 
congenital deficiency in a “platelet-stimulating factor” in her plasma. In 1978, 
Upshaw [19] reported the case of a 29-year-old female who had repeated episodes of 
thrombocytopenia and MAHA starting in childhood and was successfully treated 
with plasma infusions. Of note, both Schulman and Upshaw determined that plasma 
infusions successfully treated their patients. Rennard and Abe [20] reported a case 
that was originally identified by Upshaw with “a slightly decreased level of plasma 
cold-insoluble globulin (fibronectin) during the acute phase”, and proposed a 
nomenclature of USS for these types of patients. However, no correlation between 
the fibronectin levels and disease activity in USS patients was reported by Koizumi 
et al. [21] and Goodnough et al. [22], including Schulman’s original case. 
Furthermore, after the thrombopoietin assay was established, Miura et al. [23] 
reported 5 Japanese USS patients with a normal plasma level of thrombopoietin. 
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Thus, all the pathogenic features that were initially postulated for USS have been 
entirely excluded by subsequent investigations.  
For this reason, the term USS was almost forgotten in 1997, when the assay for 
VWF-CP (now ADAMTS13) activity was established. Instead, the practical 
diagnostic term of ‘chronic relapsing TTP (CR-TTP)’ has been historically used. This 
term was coined by Moake et al. [24], who found that UL-VWFMs were present in 
the plasma of 4 CR-TTP patients including the Upshaw’s case during the remission 
phase, but disappeared during the acute phase. In 1997, Furlan et al. [25] showed that 
4 CR-TTP patients, who were distinct from the cases of Moake et al. [24], lacked 
VWF-CP activity, but did not examine the presence of ADAMTS13 inhibitors. 
However, it was retrospectively determined that 2 CR-TTP patients in both the case 
reports by Moake et al. [24] and Furlan et al. [25] had congenital TTP, while the 
remaining 2 cases in each report had acquired TTP. Under these circumstances, we 
re-visited the term USS [11], which included analyzing 3 Japanese patients with USS, 
and found that they uniformly had a severe deficiency in VWF-CP activity 
(determined based on the VWFM assay in the presence of 1.5 mol/L urea) and no 
evidence of inhibitors. The parents of these patients were asymptomatic and had 
moderately decreased VWF-CP activity (17−60% of normal), except for one carrier 
who had very low VWF-CP activity (5.6% of normal). Later, this carrier was shown 
to have a unique single nucleotide polymorphism (SNP), a p.P475S mutation in the 
ADAMTS13 gene in one allele, which is very common among Japanese people (9.6% 
of normal individuals are heterozygous for the p.P475S mutation) [26]. 
In 2001, Levy et al. provided solid evidence that linked congenital TTP or USS 
and ADAMTS13 gene mutations [3], and simultaneously other research groups 
successfully purified this enzyme and/or cloned the encoding cDNA [2, 4, 13, 14].  
 
 
Patients, Materials and Methods 
USS patients  
Forty-three USS patients (28 females and 15 males) belonging to 38 different 
families and their family members were enrolled in this study. 
 
Assays for plasma ADAMTS13 activity and ADAMTS13 inhibitors 
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Between 1998 and 2004, our laboratory examined ADAMTS13 activity using a 
classic VWFM assay in the presence of 1.5 mol/L urea following the method of 
Furlan et al. [27]. The detection limit of this assay was 3% of the normal control [11]. 
In 2005, Kato et al. [28] developed a novel chromogenic ADAMTS13-act-ELISA 
using a recombinant VWF substrate (termed GST-VWF73-His). The detection limit 
of this assay was 0.5% of the normal control [28]. Both assays had a high correlation, 
and since then, the VWFM assay was completely replaced with the act-ELISA. In 
our patients with USS, the ADAMTS13 activity was determined at least 2 different 
occasions, using their plasmas obtained at more than 2 weeks after the last plasma 
infusion therapy. Further, In some experiments with normal individuals as described 
below, FRETS-VWF73 assays [29] were used. 
The ADAMTS13 inhibitor titers were evaluated using the Bethesda method, and 
the values less than 0.5 Bethesda U (BU)/mL were negative, but those between 0.5 
-1.0 BU/ml were assumed to be marginal.  
 
Assay for IgG-type plasma ADAMTS13 binding antibody titers 
Measurement of plasma anti-ADAMTS13 IgG antibody titers in USS-patients 
was performed by means of Ferrari et al. [30] with a slight modification as the 
followings. Briefly, the recombinant (r) ADAMTS13 was directly coated to 
micro-titer plates, and after blocking with Protein-Free Blocking Buffers (PIERCE, 
Rockford, IL), the coated plates were incubated with normal and patient plasma 
dilutions. The IgG-type antibody bound to rADAMTS13 was detected by using 
horseradish peroxidase-conjugated goat anti-human IgG (AbD Serotec, Kidlington, 
UK) with a TMB substrate kit (Thermo Scientific, Rockford, USA) at absorbance 
450 nm at room temperature for 15 min. The results were calculated as a ratio of 
sample OD at each dilution divided by normal plasma OD at each dilution. The IgG 
antibody titer of a sample corresponds to the last dilution at which the ratio is above 
the cut-off level. This assay kit was kindly provided from Drs. Barbara Plaimauer 
and Friedlich Scheiflinger of Baxter BioScience. In our laboratory, 25 normal 
plasmas (15 males and 10 males, aged between 20 and 40 years) consistently showed 
the titer of IgG-type binding antibody with a less than 25-fold dilution (shown as 
<25X in Table 1). 
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ADAMTS13 gene analysis  
All DNA analyses of the ADAMTS13 gene were performed as previously 
described [26], with permission from the Ethics Committees of both the 
sample-collecting hospitals and the institute that performed the gene analysis. 






ADAMTS13 SNPs among Japanese individuals 
The human ADAMTS13 gene is located on chromosome 9q34. The gene consists 
of 29 exons, and the translated enzyme contains 1427 amino acid residues with a 
multi-domain structure [2, 4]. To date, more than 10 SNPs in ADAMTS13 have been 
identified worldwide [3, 26]. Among these, Japanese people (n=3616) had six SNPs 
with the following allele frequencies, respectively: p.T339R (exon 9) (2.7%), 
p.Q448E (exon 12) (19.2%), p.P475S (exon 12) (5.0%), p.P618A (exon 16) (2.7%), 
p.S903L (exon 21) (4.8%), and p.G1181R (exon 25). (2.2%) [31]. Both p.T339R and 
p.P618A are almost completely linked in the general Japanese population, but this 
linkage may not exist in the Caucasian population as some reports have described 
individuals carrying p.P618A but not p.T339R [32, 33]. Plasma and rADAMTS13 
with the Asian-specific SNP, p.P475S [26, 34, 35], has markedly reduced activity 
compared to the wild-type protein in both the VWFM assay in the presence of urea 
(1.5 mol/L) [26] and the FRETS-VWF73 assay in the absence of urea [36], although 
the contribution of this polymorphism to thrombotic diseases has not been 
determined.  
Recently, we have analyzed the nucleotide sequences of ADAMTS13 in 128 
individuals without a history of TTP and identified 14 rare nonsynonymous 
mutations. Interestingly, among these 14 mutations, three mutations of p.I673F 
(exon 17), p.Q723K (exon 18), and c.3220del TACC, were also found as DCMs for 
USS in this study (below). Thus, the remaining 11 mutations may or may not be 
associated with a reduced activity of plasma ADAMTS13 [31].  
 
Natural history of 43 USS-patients in Japan 
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Until the end of March 2011, we identified 43 USS patients in 38 different families 
(Family USS-A~LL) who ranged in age from early childhood to 79 years old. Hence, 
we present an up-dated natural history of these 43 USS patients together with their 
family members (Tables 1 and 2). 
 
Family USS-A 
Patient: One male (USS-A4) born in 1999 
Brief clinical data: The history of USS-A4 (ADAMTS13 genotype: p.R268P 
/p.Q448E-p.C508Y) before he reached 5 years of age was previously described [11, 
26, 37]. He currently receives biweekly of FFP infusions (10 mL/kg BW) that are 
prepared from several fixed donors to prevent allergic reactions. He contracted the 
seasonal influenza A virus in 2010 and became severely ill with a reduced platelet 
count but did not develop overt TTP. He is currently in good clinical condition and 
has not had signs of renal or hepatic dysfunction. Both of his parents are 
asymptomatic carriers, but his father, aged 45 years old, has a p.R268P/p.P475S 
genotype and very low plasma ADAMTS13 activity at 5.6% of normal by the 
VWFM assay in the presence of 1.5 mol/L urea [26] and 3.6% by the chromogenic 
ADAMTS13-act-ELISA in the absence of urea (unpublished data). 
 
Family USS-B 
Patient: One female (USS-B3) born in 1986 
Brief clinical data: USS-B3 (ADAMTS13 genotype: p.Q449X/p.Q449X) is an only 
child who was born in Hokkaido to non-consanguineous parents. Her history prior to 
reaching 5 years of age was previously described [11, 26, 38]. Since childhood, she 
has received prophylactic FFP infusions. As a consequence, she was infected with 
hepatitis C and has received interferon therapy on two different occasions. In both 
instances, accelerated thrombocytopenia was observed despite the regular 
prophylactic FFP infusions. Furthermore, during her early childhood, she received 
DDAVP (1-desamino-8-D-arginine vasopressin) infusion once that immediately 
aggravated her clinical signs, such as hematuria and thrombocytopenia. Currently, 
her renal function is normal and her liver function is well preserved (communication 
with Dr. Mutsuko Konno). Her parents initially stated that they had a 
non-consanguineous marriage. However, a subsequent ancestral analysis revealed 
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that two great-grandparents of USS-B3 on the paternal and maternal sides migrated 
from the same area (a small fisherman’s village) of Iwate to Hokkaido at the end of 
the 19th century when Hokkaido was an undeveloped island, and the pioneers settled 
from the Japanese mainland (Honshu). This fisherman’s village is located in the 
northern part of Honshu (Tohoku) faced to Pacific sea, an area severely damaged 
several times with earthquake and tsunami in the past and most recently in March 11, 
2011. In the old days, this small village was isolated from neighbors, and was 
surrounded by mountains, suggesting that there were many consanguineous 
marriages within this village.  
 
Family USS-C 
Patient: One male (USS-C3) born in 1972 
Brief clinical data: USS-C3 (ADAMTS13 genotype: c.414+1G>A/c.414+1G>A) is 
the last of 4 children to consanguineous parents (first cousins). Notably, the patient’s 
elder brother (third sibling) died of melena soon after birth. The history of this 
patient was previously described [39, 40]. At 8 years of age, USS-C3 was clinically 
diagnosed with USS. Since then, he has received prophylactic FFP (160 mL) 
infusions every two to four weeks. However, his renal function due to chronic 
nephritis gradually deteriorated, and in 1995 he required continuous ambulatory 
peritoneal dialysis (CAPD). Because of repeated peritonitis associated with CAPD, 
his therapy for renal insufficiency was changed to hemodialysis (three times per 
week) in 1999. However, his cardiac function decreased, and he eventually died of 
chronic heart failure in 2010 at 38 years of age.  
 
Family USS-D 
Patient: One female (USS-D4) born in 1978 
Brief clinical data: USS-D4 (ADAMTS13 genotype: p.I673F/c.414+1G>A) was 
born as the second of 2 children to non-consanguineous parents. Her history was 
previously described [40, 41].  
 
Family USS-E 
Patient: One male (USS-E4) born in 1985 
Brief clinical data: USS-E4 (ADAMTS13 genotype: p.I673F/p.C908Y) was born as 
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the second of 3 children to non-consanguineous parents. His history was previously 
described [40]. The third sibling had Down’s syndrome and died of an unknown 
cause soon after birth. 
 
Family USS-F 
Patient: One male (USS-F3) born in 1993 
Brief clinical data: USS-F3 (ADAMTS13 genotype: p.R193W/c.1244+2T>G) was 
born as the first of 3 children to non-consanguineous parents. His history was 
previously described [40]. He currently receives 120 mL FFP infusions when he 
develops an occasional hemolytic crisis.  
 
Family USS-G 
Patient: One female (USS-G3) born in 1987 
Brief clinical data: USS-G3 (ADAMTS13 genotype: p.R1123C/c.686+1G>A) was 
born as the third of 4 children to non-consanguineous parents. Her history before she 
reached 14 years of age was previously described [40]. Of note, her elder sister 
(second child) had severe jaundice soon after birth and received an exchange blood 
transfusion. She died of intracranial bleeding after a trivial traffic accident when she 
was 8 years old. USS-G3 received prophylactic FFP infusions after she was 
diagnosed with USS, but the infusion intervals gradually increased. Under these 
circumstances, she became pregnant at 21 and 22 years of age. During the first 
pregnancy, she had a spontaneous abortion at 5 weeks of gestation. During the 
second pregnancy, she delivered a premature baby girl (1446 g BW) at 35 weeks of 
gestation after a cesarean section under extensive prophylactic FFP infusions (normal 
Japanese female baby at 35 weeks of gestation has a BW of median 2173g). 
Interestingly, many of placental small vessels were occupied with hyaline thrombosis 
(communication with Dr. Michiko Kajiwara, details will be published elsewhere by 
the physicians in charge). 
 
Family USS-H 
Patient: One male (USS-H3) born in 1951 
Brief clinical data: USS-H3 (ADAMTS13 genotype: p.A250V/c.330+1 G>A) was 
born to non-consanguineous parents, but the details were unclear [42]. At 51 years of 
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age, he visited a nearby hospital because of a convulsive seizure after 
hemorrhoidectomy where he was diagnosed with TTP. He had an episode of 
childhood thrombocytopenia, but there is no additional information. After 51 years of 
age, he had two episodes of overt TTP, and both were efficiently treated with FFP 
infusions. In July 2002, he experienced a fourth episode of overt TTP that developed 
after cholecystectomy, followed by gastrointestinal bleeding that was unsuccessfully 
treated with FFP infusions and further complicated by renal failure, which ultimately 
resulted in death at 52 years of age.  
 
Family USS-I 
Patient: One male (USS-I4) born in 1972 
Brief clinical data: USS-I4 (ADAMTS13 genotype: p.H234Q/p.R1206X) was born 
as the second of 2 children to non-consanguineous parents. His elder brother died at 
2 years of age with clinical signs that were compatible with TTP, as previously 
described [43]. At the age of 3 months, USS-I4 developed thrombocytopenia after 
receiving the diphtheria/pertussis/tetanus vaccine and was diagnosed with idiopathic 
thrombocytopenic purpura (ITP). Since he was 2 years old, he has experienced 
repeated overt TTP that has been treated with plasma infusions.  
 
Family USS-J 
Patient: One female (USS-J3) born in 1977 and one male (USS-J4) born in 1979, 
Brief clinical data: USS-J3 (ADAMTS13 genotype: p.R312C/c.3198delCT) and -J4 
(ADAMTS13 genotype: p.R312C/c.3198delCT) are the first and second of 3 children 
to non-consanguineous parents, respectively. For these 2 patients, severe jaundice 
was not noted during the newborn period. At 3 years of age, USS-J3 developed a 
cold followed by purpura with thrombocytopenia and was diagnosed with 
disseminated intravascular coagulation (DIC). Since then, she has experienced 
repeated episodes of thrombocytopenia and hemolytic anemia, and was diagnosed 
with CR-TTP at 6 years of age. USS-J4 had an episode of purpura and 
thrombocytopenia when he was 5 years old. In 2000, both patients were shown to 
have a severe deficiency in ADAMTS13 activity in the absence of ADAMTS13 




Patients: Two females (USS-K3 born in 1976 and USS-K4 born in 1978) 
Brief clinical data: Patients USS-K3 (ADAMTS13 genotype: p.Y304C/p.T339R- 
p.Q448E-p.G525D-p.P618A) and -K4 (ADAMTS13 genotype: p.Y304C/p.T339R- 
p.Q448E-p.G525D-p.P618A) were the first and second to 2 children of 
non-consanguineous parents, respectively. The history of these two patients was 
previously reported [12]. In 2003, USS-K3 became pregnant at 27 years old and 
developed overt TTP at 25 weeks of gestation. She experienced intrauterine fetal 
death followed by a caesarean delivery with a hysterectomy. On this occasion, she 
was diagnosed with USS. Since then, she has received prophylactic FFP infusions 
(80−120 mL) every 4 weeks in an out-patient clinic with a good clinical course. 
However, at the end of 2010, she had an H1N1 influenza A virus infection that 
remarkably aggravated thrombocytopenia and was hospitalized for treatment 
(communication with Dr. Junji Tomiyama).  
In 2003, USS-K4, the younger sibling, became pregnant 2 months after her elder 
sister. She developed mild thrombocytopenia without significant clinical signs at 22 
weeks of gestation. She received an ADAMTS13 analysis, which confirmed a 
diagnosis of USS. While being treated with FFP infusions, she delivered a premature 
baby by a cesarean section [12]. Since then, she has received FFP infusions of 80 mL 
every 3 weeks. In 2008, 5 years after her first pregnancy, USS-K4 became pregnant 
for the second time and received more frequent FFP infusions (160 mL biweekly). At 
29 weeks of gestation, her platelet count suddenly and severely dropped. Thus, at 30 
weeks of gestation, a cesarean section was performed, and she delivered a baby 
(1522g BW) with congenital heart failure due to a ventricular septum defect (details 
will be published elsewhere by the physicians in charge). 
 
Family USS-L 
Patients: Two females (USS-L2 born in 1967 and USS-L3 born in 1972) 
Brief clinical data: Both patients USS-L2 (ADAMTS13 genotype: 
p.618A-p.Q1302X/p.R125fsX6-p.T339R-p.Q448E) and -L3 (ADAMTS13 genotype: 
p.618A-p.Q1302X/p.R125fsX6-p.T339R-p.Q448E) were born as the second and 
fifth of 5 children to non-consanguineous parents. The history of these 2 patients was 
previously described [12]. At 27 years of age, USS-L2 became pregnant. At 27 
14 
weeks of gestation, she had intrauterine fetal death due to a suspected diagnosis of 
HELLP (hemolysis, elevated liver-enzymes. low platelets) syndrome. However, she 
subsequently had 4 children who were all premature and uniformly born at 
approximately 30 weeks of gestation by a cesarean section with oral aspirin. Patient 
USS-L3, the younger sister of USS-L2, was diagnosed with ITP at 3 years of age. 
She had two pregnancies at 25 and 27 years of age. However, she lost both babies at 




Patient: Two females (USS-M3 born in 1969 and USS-M4 born in 1971) 
Brief clinical data: Patients USS-M3 (ADAMTS13 genotype: p.R193W /p.R349C) 
and USS-M4 (ADAMTS13 genotype: p.R193W/p.R349C) were born as the second 
and third of 4 children to non-consanguineous parents. The history of USS-M3 was 
previously described [12]. USS-M3 was primigravida at 33 years of age, and at 20 
weeks of gestation she miscarried with overt TTP. The history of her younger sister, 
USS-M4, was also previously reported [12]. However, recently Kato et al. [44] 
reported a more detailed account of the pregnancy of USS-M4, to which we have to 
make some corrections. According to that report, USS-M4 became primigravida at 
28 years of age. Until 28 weeks of gestation, the pregnancy was uneventful when she 
suddenly stopped feeling fetal movement, resulting in intrauterine fetal death and a 
subsequent diagnosis of HELLP syndrome. One year later, at the age of 29, she 
became pregnant for the second time. She was diagnosed with ITP and treated with 
prednisolone therapy until 37 weeks of gestation, but with incremental low platelet 
counts (~23×109/L). Soon after this, she underwent a cesarean section after receiving 
concentrated platelet infusions that transiently increased her platelet counts to 
96×109/L. As a result, she delivered a healthy baby. At 32 years of age, she became 
pregnant for the third time. At 20 weeks of gestation, she developed DIC followed by 
multi-organ failure, despite extensive treatments, including platelet transfusions. By 
this time, she had been diagnosed with USS and had received an ADAMTS13 
analysis, along with her elder sister, USS-M3. At the age of 36, USS-M4 became 
pregnant for a fourth time. With extensive FFP infusions, she continued her 
pregnancy until 36 weeks of gestation and delivered a healthy baby (2506 g BW) by 
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natural birth with a skin incision [44]. 
 
Family USS-N  
Patient: One female (USS-N6) born in 1986 
Brief clinical data: Patient USS-N6 (ADAMTS13 genotype: p.H234R-p.P475S 
/c.3220delTACC) was born as the last of 4 children to non-consanguineous parents. 
She had a history of severe neonatal jaundice and childhood thrombocytopenia. Her 
clinical data were previously reported [11, 37]. Of note, she developed a thrombotic 
occlusion of the left carotid artery at 11 years of age that resulted in right hemiparesis. 
Subsequently, she developed hypertension and proteinuria, but these clinical signs 
have significantly improved during a long clinical course with prophylactic FFP 
infusions, although some neurological sequelae have persisted (communication with 
Dr. Seiji Kinoshita). 
 
Family USS-O 
Patient: One female (USS-O4) born in 1958 
Brief clinical data: Patient USS-O4 (ADAMTS13 genotype: p.I178T /p.Q929X) 
was the second of 2 children to non-consanguineous parents. The history of USS-O4 
was previously described [12]. At the age of 26, USS-O4 became pregnant. At 23 
weeks of gestation, she developed thrombocytopenia and delivered a premature 
infant at 25 weeks of gestation who died soon after birth. After delivery, she 
developed overt TTP that was rescued with plasma exchange. At 31 years of age, she 
became pregnant for the second time while receiving prophylactic FFP infusions 
every one to two weeks. At 8 weeks of gestation, she developed proteinuria and 
thrombocytopenia, and therefore received more frequent FFP infusions. At 36 weeks 
of gestation, she delivered a healthy baby girl.  
 
Family USS-P 
Patient: One male (USS-P3) born in 1971 
Brief clinical data: The clinical data for patient USS-P3  (ADAMTS13 genotype: 
p.C908Y/p.C322G-p.T323R-p.F324L, de novo mutation) were previously 
described [45]. Briefly, USS-P3 was the second of 4 children to non-consanguineous 
parents. The first and fourth siblings died of an abortion at 6 and 22 weeks of 
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gestation, respectively, due to unknown causes. At 3 years of age, USS-P3 had 
clinical signs of overt TTP, which was efficiently treated with FFP infusions. He was 
repeatedly treated with FFP infusions when overt TTP developed. Thus, after 21 
years of age, the prophylactic FFP infusions were continued.  
 
Family USS-Q 
Patient: Two males, (USS-Q1) born in 1983 and (USS-Q2) born in 1988 
Brief clinical data: Patients USS-Q1 (ADAMTS13 genotype: p.G227R-p.G1181R 
/p.C908Y) and -Q2 (ADAMTS13 genotype: p.G227R-p.G1181R/p.C908Y) were the 
first and third of 3 children to non-consanguineous parents. Their detailed clinical 
data during childhood were reported in 1990 [46].  
 
Family USS-R 
Patient: One female (USS-R5) born in 1982 
Brief clinical data: USS-R5 (ADAMTS13 genotype: p.R193W/ 
p.T339R-p.Q448E-p.A606P-p.P618A) was the last of 3 children to 
non-consanguineous parents. The history of USS-R5 was previously reported [12]. 
Briefly, at 23 years of age, she became pregnant. At 23 weeks of gestation, she 
developed mild thrombocytopenia, and at 31 weeks of gestation, she had sudden 
intrauterine fetal death. After a cesarean section, she developed overt TTP, which was 
treated with plasma exchange and steroids. On this occasion, she was diagnosed with 
USS after her ADAMTS13 activity and ADAMTS13 inhibitor status were analyzed. 
This patient did not receive prophylactic FFP infusions.  
 
Family USS-S 
Patient: One male (USS-S3) born in 1982 
Brief clinical data: USS-S3 (ADAMTS13 genotype: undetermined) was born to 
non-consanguineous parents. Neither his childhood nor family history has been 
obtained. The patient was clinically diagnosed with USS at a nearby hospital when 
he was 4 years old. Since then, he has received prophylactic FFP infusions every two 
weeks at the same hospital. In 2002, USS-S3 was confirmed to have a severe 
deficiency in ADAMTS13 activity in the absence of ADAMTS13 inhibitors. 
Furthermore, the ADAMTS13 activities for his father and mother were 34.2% and 
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Patient: One female (USS-T4) born in 1981 
Brief clinical data: USS-T4 (ADAMTS13 genotype: c.3220delTACC 
/c.3220delTACC) was born as the second of 2children to non-consanguineous 
parents. Soon after birth, she developed severe neonatal jaundice and received 
exchange blood transfusion for 3 times [47]. One month after birth, she developed 
hematuria with thrombocytopenia, which led to a clinical diagnosis of USS. She 
received DDAVP infusion once at the age of 4, by which her platelet count promptly 
dropped and her clinical signs were aggravated, in accord with a transient 
disappearance of larger VWFMs from plasma [47]. Thus, she has received 
prophylactic FFP infusions every 2 weeks since 1992. In 1998, USS-T4 was 
confirmed to have a severe deficiency in ADAMTS13 activity in the absence of 
ADAMTS13 inhibitors. She had a homozygous ADAMTS13 gene mutation of 
c.3220del TACC/c.3220delTACC (exon 24).  
 
Family USS-U 
Patient: One female (USS-U3) born in 1990 
Brief clinical data and remarks: USS-U3 (ADAMTS13 genotype: c.2259delA 
/c.2259delA) was born as the second of 2 children to consanguineous parents 
(second cousins). Soon after birth, she developed severe neonatal jaundice that 
required an exchange transfusion. She was clinically diagnosed with USS at 4 
months of age. In 1998, USS-U3 was confirmed to have a severe deficiency in 
ADAMTS13 activity but no ADAMTS13 inhibitors. She was homozygous for an 
ADAMTS13 gene mutation of c.2259delA/c.2259delA (exon 19). This patient has 
continued prophylactic FFP infusions. 
 
Family USS-V 
Patient: One female (USS-V3) born in 1983 
Brief clinical data: USS-V3 (ADAMTS13 genotype: p.W1081X/p.R193W) was 
born as the second of 2 children to non-consanguineous parents. Soon after birth, she 
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developed severe neonatal jaundice that required an exchange blood transfusion. She 
was clinically diagnosed with USS at 4 years of age. In 1998, USS-V3 was 
confirmed to have a severe deficiency in ADAMTS13 activity but no ADAMTS13 
inhibitors. She had a compound heterozygous ADAMTS13 gene mutation with 
p.W1081X (exon 24) from her father and p.R193W (exon 6) from her mother. The 
patient has been administered FFP infusions on demand. 
 
Family USS-W 
Patient: One female (USS-W4) born in 1990 
Brief clinical data and remarks: USS-W4 (ADAMTS13 genotype: 
p.Q448E-p.G550R/p.P475S) was born as the second of 2 children to 
non-consanguineous parents. She did not have episodes of severe jaundice as a 
newborn. At 2 years of age, she developed pneumonia followed by 
thrombocytopenia. Since then, she has had repeated episodes of thrombocytopenia 
and hemolytic anemia that have coincided with various infections, resulting in a 
diagnosis of Evans syndrome. In 2005, USS-W4 was confirmed to have a severe 
deficiency in ADAMTS13 activity in the absence of ADAMTS13 inhibitors. An 
ADAMTS13 gene analysis in USS-W4 suggested that she was a compound 
heterozygote with a p.G550R (exon 14) mutation from her father and an unidentified 




Patient: One female (USS-X5) born in 1963 
Brief clinical data: USS-X5 (ADAMTS13 genotype: p.G1181R/p.P475S) was the 
last of 4 children to non-consanguineous parents. She did not have severe neonatal 
jaundice or childhood thrombocytopenia. She had two pregnancies at the ages of 24 
and 26 years that yielded two children. During her first pregnancy, she had 
pregnancy-induced hypertension, but the details are unknown. At 32 years of age, 
she developed nephrotic syndrome, followed by repeated hemolytic anemia and 
thrombocytopenia of an unknown cause. None of the laboratory markers were 
indicative of connective tissue disease. She underwent a splenectomy at the age of 36. 
In 2004, she had a relapse of nephrotic syndrome with hemolytic anemia and 
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thrombocytopenia that was treated with high-dose steroid therapy with limited 
success. At this time, her plasma ADAMTS13 activity levels and ADAMTS13 
inhibitor status were examined, and she was determined to have a severe deficiency 
in ADAMTS13 activity in the absence of ADAMTS13 inhibitors. The same results 
were obtained 6 months later with a different plasma specimen. An ADAMTS13 gene 
analysis in USS-X5 identified no DCMs, but revealed two SNPs of p.P475S from her 
mother and p.G1181R from her father. In 2007, she developed systemic lupus 
erythematosus (SLE) and was moved to a different hospital, after which we were 
unable to follow her clinical and laboratory data. From these results, USS-X5 could 
be considered to be a possible USS. 
 
Family USS-Y 
Patient: One female (USS-Y3) born in 1960 
Brief clinical data: USS-Y3 (ADAMTS13 genotype: p.G385E/ p.R1206X) was the 
last of 3 children to non-consanguineous parents. It is unclear whether this patient 
had a history of severe neonatal jaundice. However, during childhood she had an 
episode of thrombocytopenia and was diagnosed with ITP. She has a history of fresh 
whole blood transfusions, although the details are unclear. Since then, she had no 
remarkable changes. However, at 45 years of age, she suddenly developed 
thrombocytopenia and hemolytic anemia, leading to a diagnosis of Evans syndrome. 
On this occasion, her physician noted many schistocytes on her blood film, and 
USS-Y3 was confirmed to have a severe deficiency in ADAMTS13 activity in the 
absence of ADAMTS13 inhibitors. An ADAMTS13 gene analysis determined that she 
was a compound heterozygote with p.G385E (exon 10) from her father and 
p.R1206X (exon 26) from her mother.  
 
Family USS-Z 
Patient: One female (USS-Z3) born in 1971  
Brief clinical data: USS-Z3 (ADAMTS13 genotype: p.R193W /p.R193W) was the 
last of 3 children to consanguineous parents (second cousins). Her clinical data were 
previously described [12]. Briefly, she became pregnant for the first time at 25 years 
of age, and at 12 weeks of gestation, she developed thrombocytopenia and was 
diagnosed with pregnancy-associated ITP. At 32 weeks of gestation, she had a live 
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birth by cesarean section, and then developed overt TTP, which was treated with 
daily plasma exchange. This patient was referred to our laboratory in 1998, and 
USS-Z3 was confirmed to have a severe deficiency in ADAMTS13 activity in the 
absence of ADAMTS13 inhibitors. This patient did not receive prophylactic FFP 
infusions, and she had more than five TTP episodes between 1998−2005. Each 
episode was treated with 320 mL plasma infusions. She has been receiving 
prophylactic FFP infusions every two weeks. 
 
Family USS-AA 
Patient: One female (USS-AA3) born in 1987 
Brief clinical data: USS-AA3 (ADAMTS13 genotype: not performed) was the first 
of 2 chidren born to non-consanguineous parents. She had neither an apparent history 
of severe neonatal jaundice nor thrombocytopenia during childhood. At 19 years of 
age, she suddenly developed petechiae, and her laboratory data indicated severe 
thrombocytopenia and hemolytic anemia. Thus, her ADAMTS13 activity was 
examined and revealed a severe deficiency in ADAMTS13 activity but no 
ADAMTS13 inhibitors. Plasma exchange therapy was performed, and her platelet 
counts normalized. One month later, her ADAMTS13 activity and ADAMTS13 
inhibitor status were re-tested and yielded the same results. In addition, her family 
members had the following ADAMTS13 activities: father (32%), mother (53%), and 
younger sister (46%). An ADAMTS13 gene analysis was not performed in this family 
because permission was not obtained. In 2009, we determined that USS-AA3 had a 
normal platelet count (201×109/L), but her ADAMTS13 activity was still very low 
(<0.5% of normal) with no ADAMTS13 inhibitors. Since this point, we have been 
unable to obtain more up-dated information on this patient. 
 
Family USS-BB 
Patient: One male (USS-BB3) born in 1947 
Brief clinical data: USS-BB3 (ADAMTS13 genotype: p.R193W/p.R193W) was the 
first of 3 children to consanguineous parents (first cousins). His younger sister died 
of ‘purpura of unknown cause’ at 23 years of age. It is unclear whether USS-BB3 
experienced episodes of severe jaundice as a newborn or childhood 
thrombocytopenia. He was married and had 3 children. At 55 years of age, he 
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developed overt TTP, which was successfully treated with plasma exchange. When 
he was 59 years old, he developed hematuria and was admitted to a nearby hospital, 
where an ADAMTS13 analysis showed that he had a severe deficiency in 
ADAMTS13 activity but no ADAMTS13 inhibitors. An ADAMTS13 gene analysis 
indicated that he was a homozygote with p.R193W (exon 6) (communication with 
Dr. Toshi Imai, details will be reported by the physicians in charge). 
 
Family USS-CC 
Patient: One male (USS-CC5) born in 2004 
Brief clinical data: USS-CC5 (ADAMTS13 genotype: p.Q723K/p.R398C) was the 
last of 3 children to non-consanguineous parents. Soon after birth, he developed 
Coombs-negative hemolytic anemia and was treated with an exchange blood 
transfusion. At 7 months of age, he became infected with influenza A virus that 
aggravated his thrombocytopenia and hemolytic anemia. At 32 months of age, he 
suddenly developed a transient disturbance in his ability to walk and converse. On 
this occasion, an ADAMTS13 analysis revealed that USS-CC5 had a severe 
deficiency in ADAMTS13 activity but no ADAMTS13 inhibitors. An ADAMTS13 
gene analysis indicated that he was a compound heterozygote with p.Q723K (exon 
18) from his father and p.R398C (exon 10) from his mother. Since he was diagnosed 
with USS, he has received prophylactic FFP infusions every two weeks.  
 
Family USS-DD 
Patient: One female (USS-DD5) born in 2007 
Brief clinical data: USS-DD5 (ADAMTS13 genotype: p.R268P/p.Y304C) was born 
as the last of 3 children to non-consanguineous parents. One day after birth, the 
patient developed hematuria, petechiae, moderate jaundice, and thrombocytopenia, 
suggesting immune thrombocytopenia. A platelet transfusion was performed that 
subsequently aggravated her jaundice, which was ameliorated with albumin infusions 
and phototherapy from three directions. Therefore, an exchange blood transfusion 
was not performed. Her platelet counts were maintained around 60−100×109/L, and 
at 15 days of age the physician infused FFP at a dose of 10 mL/kg due to suspected 
USS. This treatment markedly increased her platelet counts (written information 
from Dr. Hitoshi Miyabayashi). One month after birth, an ADAMTS13 analysis 
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showed that the patient had a severe deficiency in ADAMTS13 activity but no 
ADAMTS13 inhibitors. An ADAMTS13 gene analysis determined that USS-DD5 
was a compound heterozygote with p.R268P (exon 7) from her father and p.Y304Y 
(exon 8) from her mother. The patient did not receive prophylactic FFP infusions. 
 
Family USS-EE 
Patient: One male (USS-EE4) born in 2003 
Brief clinical data and remarks: USS-EE4 (ADAMTS13 genotype: 
c.2259delA/c.2259delA) was born as the second child of bi-ovular twins by a 
caesarean delivery at 37 weeks of gestation to consanguineous parents (second 
cousins). Soon after birth, USS-EE4 received an exchange blood transfusion under a 
diagnosis of DIC. However, the other twin did not have these complications. Since 
then, USS-EE4 has continued to experience mild thrombocytopenia. At 18 months of 
age, his platelet count dropped to 11×109/L, and schistocytes appeared on a blood 
film when the patient had a rotavirus infection. The patient subsequently experienced 
repeated episodes of thrombocytopenia and hemolytic anemia associated with a 
variety of infectious diseases. At the age of 4 years and 7 months, the patient was 
admitted to a nearby hospital because of exacerbated asthmatoid bronchitis together 
with severe thrombocytopenia (4×109/L). After being diagnosed with ITP, the patient 
was administered high-dose immunoglobulin therapy with steroid therapy, but there 
was no clinical improvement (written information from Dr. Masahiro Migita). An 
ADAMTS13 analysis showed a severe deficiency in ADAMTS13 activity but no 
ADAMTS13 inhibitors. An ADAMTS13 gene analysis in USS-EE4 identified a 
homozygous mutation of c.2259delA (exon 19). This patient did not receive 
prophylactic FFP infusions. 
 
Family USS-FF 
Patient: One female (USS-FF3) born in 1991 
Brief clinical data: USS-FF3 (ADAMTS13 genotype: p.Q449X/p.Q449X) was born 
as the first of 2 children to non-consanguineous parents [48]. As a newborn, the 
patient had moderate jaundice that required phototherapy, but no exchange blood 
transfusion was required. She also had a history of chronic thrombocytopenia as a 
newborn, but did not receive specific treatment. At 6 years of age, she developed 
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severe thrombocytopenia and hemolytic anemia, and an ADAMTS13 analysis 
revealed a severe deficiency in ADAMTS13 activity but no ADAMTS13 inhibitors. 
An ADAMTS13 gene analysis was performed at the laboratory of Dr. David Ginsburg, 
where a homozygous mutation of p.Q449X (exon 6) was identified ([40] and written 
communication with Dr. Yoji Sasahara). Since the USS diagnosis was confirmed, the 
patient has received FFP infusions (5 mL/kg) every two weeks. 
 
Family USS-GG 
Patient: One male (USS-GG2) born in 1931 
Brief clinical data: USS-GG2 (ADAMTS13 genotype: p.C1024R/p.C1024R) was 
born as the fifth of 7 children to consanguineous parents (first cousins). The 
ancestors of this family can be traced back to Kochi on Shikoku Island. The first two 
siblings died of an unknown etiology during childhood. Interestingly, USS-GG2 
suddenly developed overt TTP with neurological signs at 63 years of age and was 
admitted to a nearby hospital. Before this, he had never had an episode of anemia or 
thrombocytopenia. He was treated with plasma infusions because plasma exchange 
was not readily available at that hospital. The next day, his neurological signs 
dramatically improved. He subsequently has experienced repeated episodes of overt 
TTP, resulting in a clinical diagnosis of CR-TTP, which was treated with biweekly 
prophylactic FFP infusions (320−480 mL per each). However, at 77 years of age, he 
had cerebellar bleeding. Thus, he received an ADAMTS13 analysis that showed a 
significant reduction in ADAMTS13 activity (2.4−3.4% of normal on 3 different 
occasions) but no ADAMTS13 inhibitors. An ADAMTS13 gene analysis revealed 
that he was a p.C1024R/p.C1024R (exon 24) homozygote, confirming the USS 
diagnosis. Under prophylactic FFP infusions, he was alive until 79 years old, but he 
suddenly died of stroke in 2011 at the age of 79 (communication with Dr. Fumihiro 
Taguchi, details will be published elsewhere by the physician in charge). 
 
Family USS-HH 
Patient: One female (USS-HH4) born in 2003 
Brief clinical data: USS-HH4 (ADAMTS13 genotype: p.Q449X/ c.4119delG) was 
born as the second of 2 children to non-consanguineous parents. Soon after birth, she 
developed Coombs-negative hemolytic anemia that was treated with an exchange 
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blood transfusion. In 2005, she had three episodes of thrombocytopenia and 
hemolytic anemia that occurred concomitantly with fever or the chicken pox. 
Therefore, her ADAMTS13 activity was assayed, and she was determined to have a 
severe deficiency in ADAMTS13 activity but no ADAMTS13 inhibitors. An 
ADAMTS13 gene analysis revealed that she was a compound heterozygote with 
p.Q449X (exon 12) from her father and c.4119delG (exon 29) from her mother. 
Although she had a history of severe neonatal jaundice followed by an exchange 
blood transfusion, she subsequently has only had mild clinical signs and has not 
received prophylactic FFP infusions. She receives FFP infusions only when her 
platelet count severely drops. 
  
Family USS-II 
Patient: One female (USS-II3) born in 1977 
Brief clinical data: USS-II3 (ADAMTS13 genotype: not performed) was born by a 
cesarean section as the fourth and final pregnancy of her mother at 40 weeks of 
gestation. Her parents were non-consanguineous. Her mother had previously had two 
abortions (5 and 3 months of gestation) and a stillbirth (9 months of gestation) before 
USS-II3 was born. On the second day after birth, USS-II3 was treated with an 
exchange blood transfusion because of severe jaundice and thrombocytopenia. One 
month later, the patient was discharged but the thrombocytopenia continued, 
suggesting ITP. Since then, she has received whole blood transfusions when her 
platelet counts have dropped to 10×103/L. At 9 months of age, the patient was 
clinically diagnosed with TTP. She was administered FFP infusion when severe 
thrombocytopenia developed. At 10 years of age, she underwent a splenectomy but 
there was no clinical improvement. The prophylactic FFP infusions have continued. 
At 21 years of age, she was diagnosed with USS after it was determined that she had 
a severe deficiency in ADAMTS13 activity but no ADAMTS13 inhibitors. She 
currently receives prophylactic FFP infusions (120 mL) every week.  
 
Family USS-JJ 
Patient: One male (USS-JJ3) born in 1980 
Brief clinical data: USS-JJ3 (ADAMTS13 genotype: c.1885delT/p.C908Y) was 
born as the last of 4 children to non-consanguineous parents. He had no history of 
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exchange blood transfusions as a newborn. At 2 years of age, he suddenly 
complained of abdominal pain and developed hemolytic anemia, hematuria, and 
thrombocytopenia. On this occasion, he was diagnosed with acute renal insufficiency 
due to diarrhea-negative atypical HUS at a nearby hospital. Under this diagnosis, he 
received conservative therapy, including heparin, anti-platelet drugs, and red blood 
cell transfusion, but no platelet or FFP infusions. During the next 14 years, he 
occasionally experienced overt HUS. At 12 years of age, his physician noticed that 
the FFP infusions were highly effective and improved his clinical manifestations, 
suggesting a clinical diagnosis of CR-TTP. Since 1996, he has received FFP 
infusions (160−240 mL per each) when his platelet counts have dropped below 
100×109/L, and has been administered FFP infusions with a greater volume 
(320−480 mL) during instances of overt TTP. In 1998, he was diagnosed with USS 
after an ADAMTS13 analysis revealed a severe deficiency in ADAMTS13 activity 
but no ADAMTS13 inhibitors. Furthermore, he was a heavy drinker, which increased 
the frequency of overt TTP. Under these unhealthy conditions, the prophylactic FFP 
infusions were sometimes interrupted. Thus, when he was 25 years old, he 
experienced a cerebral infarction and the prophylactic FFP infusions were re-started. 
Nevertheless, one year later, he had severe renal insufficiency that required 
hemodialysis. Thus, he currently receives maintenance dialysis therapy and 
prophylactic FFP infusions of 240 mL per week. In 2009, an ADAMTS13 activity 
analysis revealed a severe deficiency in ADAMTS13 activity but no ADAMTS13 
inhibitors. An ADAMTS13 gene analysis revealed that he was a compound 
heterozygote with c.1885delT (exon 16) and p.C908Y (exon 21), but that was not 
performed to his parents. 
 
Family USS-KK 
Patient: One female (KK3) born in 1976  
Brief clinical data: USS-KK3 (ADAMTS13 genotype: not performed) was born as 
the second of 3 children to non-consanguineous parents. She had no history of 
exchange blood transfusion during the newborn period. At the age of 2, she 
developed thrombocytopenia and was diagnosed of ITP. She received a steroid 
therapy for thrombocytopenia at the age of 17 but without improvement, and then 
received splenectomy. When she was a university student at the age of 20, she 
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developed thrombocytopenia and hemolytic anemia after heavily drinking alcohol, 
and on this occasion she was clinically diagnosed of TTP at Shinshu university 
hospital in Nagano. A diagnosis of CR-TTP was made by Dr. Miha Furlan at 
University of Bern in 1998, after analyzing ADAMTS13, which showed a severe 
deficiency of the activity but without its inhibitors (these results were re-confirmed 
in March 2011 using chromogenic act-ELISA). Her mother and two siblings had a 
slightly decreased ADAMTS13 activity (25~50%) (communication with Drs. 
Fumihiro Ishida and Hikaru Kobayashi). Now, the patient receives the prophylactic 
FFP infusions (240 ml per each) every 3 weeks. The ADAMTS13 gene analysis has 
not been performed. 
 
Family USS-LL 
Patient: One female (LL4) born in 1981.  
Brief clinical data: USS-LL4 (ADAMTS13 genotype: 
p.C438S/p.T339R-p.Q448E-p.P618A-p.G909R) was born as the last of 2 children to 
non-consanguineous parents. She had no history of exchange blood transfusion 
during the newborn period. At the age of 14, she was diagnosed of HUS of unknown 
etiology, and received hemodialysis. During 1996-2001, she repeated overt TTP 
when she had various infectious diseases, and in each occasion she was treated with 
FFP infusions. In 2002, she was diagnosed of USS after analyzing ADAMTS13, 
showing a severe deficiency of the activity but without its inhibitors in our laboratory. 
Since then, however, a low-titer ADAMTS13 inhibitor (less than 1.4 BU/mL) was 
detected in a few occasions, but its clinical significance was not well evaluated. Her 
parents and elder sister are asymptomatic and have a slightly decreased ADAMTS13 
activity (27~57%). The ADAMTS13 gene analysis in this patient revealed a 
compound heterozygote of p.C438S (exon 12) from her father and p.G909R (exon 
21) from her mother. She had been treated with FFP infusions on demand. Most 
recently, she has become pregnant, and her inhibitor titers are kept below 0.5 BU/ml. 
Thus, the prophylactic FFP infusions (10 ml/kg BW) have been started biweekly, and 
so far no increase of ADAMTS13 inhibitor titer has been observed (communication 
with Dr. Yoshiyuki Ogawa). 
 
Characterization and allelic numbers of ADAMTS13 gene mutations in Japanese 
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patients with USS 
Of our 43 USS-patients, 39 received an ADAMTS13 gene analysis while it was 
not performed in 4 patients (USS-S3, AA3, II3 and KK3). Nine of these 39 
USS-patients were homozygous for ADAMTS13 gene mutations, and 29 were the 
compound heterozygotes, including one patient (USS-W4) with p.G550R mutation 
on one allele while DCM on the other allele was unidentified. In the remaining one 
patient (USS-X5), two SNPs (p.P475S/p.G1181R) but not DCMs were identified on 
each allele. Of these 39 USS-patients, five were siblings that each belonged to 
different families. Thus, the 65 [2 × (39−5)-3] allelic numbers of DCMs in these 
patients are summarized in Table 3. Interestingly, these mutations are quite different 
from those reported in the US and Western countries [3, 49-66], except for p.R268P. 
However, the p.R349C mutation was previously reported in a Chinese USS patient 
in Hong Kong [67], and c.330+1G >A was identified in a Korean patient [68]. Thus, 
it is likely that specific ADAMTS13 gene mutations are more common among certain 
ethnicities. In this regard, the mutation of p.R268P is quite unique, because of the 
same mutation was reported by Veyradier et al. [55] in France, but in a Haitian 
patient.  
The ADAMTS13 gene mutation with the highest frequency in Japan was 
p.R193W (n=8), followed by the remaining alleles in order of descending frequency: 
p.Q449X (n=5), p.C908Y (n=4), c.2259delA (n=4), etc. The p.Q449X mutation was 
localized to the northern part (Tohoku) of Honshu, c.2259delA to Kyushu, p.C908Y 
to western Japan, and p.R193W to a relatively wide area across Japan but more 
frequently in western Japan, suggesting some geographical specificity in these 
mutations. (Fig. 1) 
 
Plasma levels of ADAMTS13 activity, ADAMTS13 inhibitor, and IgG-type 
anti-ADAMTS13 binding antibody in USS-patients 
Most of our USS-patients had the plasma levels of ADAMTS13 activity with a 
less than 0.5% of the normal (Table 1), but USS-GG2 alone had the ADAMTS13 
activity of 2.4-3.4% of the normal, measured in 3 different occasions, as described 
above. Further, seven USS-patients (USS-F3, J3, K3, H3, Q1, S3, and LL4) had a 
trace amount of ADAMTS13 activity (0.6-1.8% of the normal) in some occasions, of 
whom 4 patients (USS-J3, K3, Q1, and LL4) had the ADAMTS13 activity below 
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0.5% of the normal in different occasions The reason for this slight variation of 
plasma ADAMTS13 activity in our patients is presently unknown. 
As for the ADAMTS13 inhibitors, all of our USS-patients had the plasma level 
of less than 0.5 BU/ml, but with one exception (USS-LL4), who showed the inhibitor 
titers ranging from less than 0.5 to 1.4 BU/ml. 
In regard to the IgG-type anti-ADAMTS13 binding antibody, 36 of 43 
USS-patients did not have it (shown as the titer of 25X or less than 25X in Table 1). 
However, 7 patients (USS-K3, K4, X5, AA3, EE4, II3, and LL4) had the antibody 
titers ranged from 50X to 400X in some occasions. Clinical significance of the 
IgG-type anti-ADAMTS13 binding antibody is also unclear at moment, but notably 6 




Since ADAMTS13 was originally discovered, one major question has been why 
USS-patients who consistently lack ADAMTS13 activity do not always experience 
acute symptoms of overt TTP. Furthermore, symptoms often become evident only 
when the patients have infections or become pregnant [12, 69]. In both instances, 
vascular endothelial cell injury may be involved, and these cases have been 
indirectly associated with elevated plasma levels of cytokines or soluble 
thrombomodulin [70]. Consistent with these observations, studies on two different 
groups of ADAMTS13 gene knock-out mice revealed that UL-VWFMs were 
detectable in the blood, although the mice did not exhibit acute symptoms [71, 72]. 
Considering these results, investigators have assumed that a deficiency in 
ADAMTS13 activity is prothrombotic, but alone is insufficient to provoke acute 
symptoms. Thus, second hits or triggers must exist. Related to this hypothesis, it has 
been said that there are two clinical features of USS, termed the “early-onset” and 
“late-onset” phenotypes. To partially address this question, we have extensively 
analyzed the natural histories and ADAMTS13 genotypes of 43 Japanese patients 
with USS.  
This study has two advantages. One advantage is that Japan has four basic small 
islands, Hokkaido, Honshu, Shikoku, and Kyushu, that are favorable for tracing the 
ancestral roots of a targeted USS family. This is because USS patients tend to live 
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near their parents or healthy relatives in order to receive medical support when they 
develop overt signs of TTP. In fact, before ADAMTS13 was discovered in 2001, nine 
patients were clinically diagnosed with USS or congenital CR-TTP in Japan, and 
none of these patients have moved to other areas or countries. The other advantage of 
this study can be attributed to the development of two convenient ADAMTS13 
activity assays in our country, FRETS-VWF73 [29] and the chromogenic 
ADAMTS13-ac-ELISA [28]. Both assays are now used worldwide, and in 1998 Nara 
Medical University started voluntarily using the VWFM assay to meet the requests 
of clients across Japan. In 2005, the act-ELISA shortened the time required to 
diagnose TTP, and more importantly facilitated the identification of new 
USS-patients in Japan.  
Although severe neonatal jaundice that requires exchange blood transfusion has 
been a hallmark of USS, this clinical sign was present in 18 of 43 (42%) patients in 
this study. Because of this clinical sign, 4 (/18) physicians correctly diagnosed their 
patient with USS before the patient reached 6 months of age, and 10 (/18) physicians  
required 6 years to reach a USS diagnosis. On the other hand, among 25 USS 
patients without severe newborn jaundice, two (/25) were correctly diagnosed within 
6 months of age, and six (/25) were diagnosed within 6 years. As a whole, 25 of 43 
(58%) USS patients were correctly diagnosed before they reached 15 years of age, 
including 12 females and 13 males, indicating that there is no gender disparity in 
diagnosing USS during childhood. These 25 patients would be unanimously 
considered to have the “early-onset phenotype”. However, the remaining 18 USS- 
patients were diagnosed after 15 years of age. This raises the question of whether 
these patients were the true “late-onset phenotype” or not. One particularly 
interesting result was that 15 (/18) patients were diagnosed between 15 and 45 years 
of age, and interestingly they were all female. Furthermore, among these 15 female 
patients, nine were diagnosed in association with pregnancy. On the other hand, the 
remaining 3 patients (USS-H3, -BB3, and –GG2) were diagnosed after 45 years of 
age, and they were all male, which sharply contrasts the previous scenario. Thus, the 
natural history of these 3 male patients appeared to be an excellent means to analyze 
the pathogenesis of the “late-onset phenotype”. Among these patients, USS-H3 with 
a p.A250V/c.330+1G>A genotype had an episode of thrombocytopenia, but there are 
few clinical details and the patient died of renal failure in 2002 [42], Thus, no further 
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results on USS-H3 are available.  
However, two other males, USS-BB3 and USS-GG2, had received annual health 
examinations during adulthood, and there were no apparent abnormalities until 
sudden and overt TTP developed at 55 and 63 years of age, respectively. This may 
indicate that the clinical signs of TTP were very mild during their childhood and 
adulthood, and any symptoms might have been attributed to isolated mild 
thrombocytopenia. Interestingly, these two elderly men carried two different 
homozygous ADAMTS13 gene mutations, p.R193W/p.R193W and 
p.C1024R/p.C1024R, respectively. We previously reported that the p.R193W protein 
was present in the plasma of patient USS-Z3 [12, 73]. In this study we also 
determined that the p.C1024R protein was present in the plasma of patient USS-GG2 
(data not shown). Furthermore, in vitro expression studies using HeLa cells that were 
transfected with either of these two mutant gene plasmids showed that each protein 
was consistently secreted into the culture medium but had much reduced activity 
compared to the wild-type protein ([39] and unpublished data). Consistent with these 
observations, the ADAMTS13 activity of patient USS-GG2 was mildly reduced 
(2.4−3.4% of the normal) on 3 different occasions. As for the homozygous 
p.R193W/p.R193W mutation, we identified another female patient (USS-Z3) who 
was correctly diagnosed with USS at 27 years of age as a result of 
pregnancy-associated TTP at 25 years of age. Her past history was well recorded, 
and indicated that she had mild jaundice as a newborn and thus did not receive an 
exchange blood transfusion. However, she was diagnosed with ITP with isolated 
thrombocytopenia at 7 years of age. Taken together, these results indicate that the 
phenotype of the homozygous p.R193W/p.R193W mutation is mild. Therefore, 
patients carrying this mutation would presumably have mild thrombocytopenia 
during childhood, as shown in USS-Z3, unless they are exposed to strong stimuli 
such as a cytokine storm during influenza virus infection. However, after 
adolescence the gender disparity apparently determines the fate of these 
USS-patients. Pregnancy undoubtedly is a strong inducer of overt TTP in female 
USS-patients, although the pathogenesis is not fully elucidated. However, it is now 
well established that plasma VWF levels remarkably increase as gestation progresses, 
along with the appearance of UL-VWFMs, which are accompanied by reduced 
ADAMTS13 activity due to consumption, even in normal pregnant women [74,75]. 
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Thus, in pregnant USS women, an enormous excess of the substrate (larger VWFM) 
relative to the ADAMTS13 enzyme is the most plausible pathogenic mechanism. 
As a consequence, our studies here have re-confirmed that pregnancy, influenza 
infection, and DDAVP administration can be the strong triggers inducing overt TTP 
in USS-patients. Besides, now it is indicated that the aging, interferon therapy, and 
heavily drinking alcohol could be the additional modifiers aggravating clinical signs 
of USS-patients.  
Given that the p.R193W mutation is a frequent DCM for USS in Japan, male 
patients carrying this mutation might not exhibit clinical signs of thrombosis at a 
younger age. However, as they age, multi-factorial endogenous and exogenous 
causes mentioned above would facilitate thrombotic events, leading to brain 
infarctions and chronic renal failure as a result of microcirculation disturbances. We 
speculate that thrombotic events in the brain or kidney, which still have an unknown 
pathogenesis, might result from ADAMTS13 gene abnormalities. Our examination of 
the natural history in this large cohort of USS-patients with ADAMTS13 mutations 
may shed light on these important diseases. Thus, here we emphasize again an 
importance of the assay for ADAMTS13 activity as a routine test to make and/or 
exclude a diagnosis of USS, when physicians meet the patients with 
thrombocytopenia of unknown etiology, not only in childhood but also in adulthood. 
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Figure 1. Geographical distribution of 43 Japanese patients with USS and their 
ADAMTS13 gene mutations. 
Among 43 USS patients, an ADAMTS13 gene analysis was performed in 39 patients. 
Nine of the 39 USS patients had homozygous ADAMTS13 gene mutations, and 29 
were the compound heterozygotes, including one patient (USS-W4: patient no 28) 
with disease-causing mutation (DCM) on one allele while the other was unidentified. 
In the remaining one patient (USS-X5: patient no 29), two single nucleotide 
polymorphisms (SNPs), p.P475S and p.G1181R, but not DCMs were identified on 
each allele. The p.Q449X mutation localized to the northern part (Tohoku) of 
Honshu, c.2259delA to Kyushu, p.C908Y to western Japan, and p.R193W to a 
relatively wide area across Japan. Circled numbers indicate the patients shown in 
Table 1 and 2. 
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